title: Redefining treatment options in chronic hand eczema (CHE).
authors.affiliation: Innovaderm Research, Montreal, QC, Canada.
authors.forename: Robert
authors.initials: R
authors.lastname: Bissonnette
authors.forename: Thomas L
authors.initials: TL
authors.lastname: Diepgen
authors.forename: Peter
authors.initials: P
authors.lastname: Elsner
authors.forename: John
authors.initials: J
authors.lastname: English
authors.forename: Robin
authors.initials: R
authors.lastname: Graham-Brown
authors.forename: Bernhard
authors.initials: B
authors.lastname: Homey
authors.forename: Thomas
authors.initials: T
authors.lastname: Luger
authors.forename: Charles
authors.initials: C
authors.lastname: Lynde
authors.forename: Jürgen
authors.initials: J
authors.lastname: Maares
authors.forename: Howard I
authors.initials: HI
authors.lastname: Maibach
mesh_terms: D000279:Administration, Cutaneous; D000284:Administration, Oral; D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000368:Aged; D000077556:Alitretinoin; D002908:Chronic Disease; D004485:Eczema / Q000175:diagnosis / Q000628:therapy*; D019317:Evidence-Based Medicine; D005260:Female; D005500:Follow-Up Studies; D006229:Hand Dermatoses / Q000175:diagnosis / Q000628:therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D016032:Randomized Controlled Trials as Topic; D012176:Retinoids / Q000627:therapeutic use; D018570:Risk Assessment; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014212:Tretinoin / Q000627:therapeutic use*; D055815:Young Adult
chemical_list: D000305:Adrenal Cortex Hormones; D007166:Immunosuppressive Agents; D012176:Retinoids; D000077556:Alitretinoin; D014212:Tretinoin